BACKGROUND: Overall survival (OS) is considered the gold standard for determining treatment efficacy in oncology trials, but the relation between treatment and OS can be challenging to assess because of long study durations and the impact of subsequent therapies on outcome. Using OS can be particularly difficult for new therapies in hematologic malignancies (HMs). METHODS: This retrospective analysis was conducted to characterize the primary endpoints used to support US Food and Drug Administration (FDA) approvals for new drug or novel HM indications between January 2002 and July 2015. Data on approvals were retrieved from the FDA and CenterWatch websites, and from the FDA prescribing information on respective products at the time of approval. RESULTS: Sixty-three FDA approvals involving 35 drugs and 16 HMs were identified. Of the 63 approvals, 45 (71.4%) included response rate (RR), and 17 (27%) included progression-free survival (PFS; n 5 14) or time to progression (n 5 3), and 1 approval included OS. Twenty-three approvals (36.5%) included trials with an active comparator arm. The median relative magnitude of benefit versus comparator was 71% improvement (range, 26%-127%), with a median hazard ratio of 0.55 (range, 0.16-0.72). CONCLUSIONS: FDA approvals for new drug or novel HM indications are often based on endpoints other than OS, such as RR and PFS. Tools for determining the magnitude of clinical benefit and treatment value in HMs should take into account the importance of RR, PFS, and other non-OS endpoints. Cancer 2017;123:1689-94.
INTRODUCTION
The gold standard for the approval of novel cancer therapies is the demonstration of increased overall survival (OS) compared with the current standard of care. 1, 2 The American Society of Clinical Oncology and the European Society for Medical Oncology (ESMO) have recently developed tools for assessing the magnitude of clinically meaningful benefit of a given therapy and its therapeutic value. 3, 4 Both tools specify improvement in OS as the most important indicator of treatment efficacy; however, the ESMO tool was specifically developed for use with solid tumors only; therefore, the ESMO guidelines may not apply to all cancers. Assessment of OS in hematologic malignancy (HM) studies requires a long follow-up period, which can be confounded by multiple subsequent lines of therapy; as such, other endpoints may be more meaningful as indicators of clinical benefit in HMs. Therefore, leading clinicians have worked with the US Food and Drug Administration (FDA) to establish non-OS endpoints like progression-free survival (PFS) and response rate (RR), which may be used as appropriate endpoints for the regulatory approval of treatments for HMs. 1, 2, 5 The objectives of this report were to retrospectively review the endpoints used in clinical trials supporting FDA drug approvals for HMs and to provide a perspective on their applicability in value assessments.
MATERIALS AND METHODS

Study Design
For this retrospective analysis, we reviewed new drugs and novel indications for approved drugs that were approved by the FDA for HMs between January 2002 and July 2015. Information on approvals was retrieved from the FDA and CenterWatch websites; FDA prescribing information on respective products at the time of approval was also included. For each approval, the following information was collected: date of approval; therapy area; type of approval (initial vs expanded and regular vs accelerated); primary endpoint; trial design, including use of a comparator arm; and outcome measure. For trials that included a comparator arm, outcomes in each treatment arm were collected to assess the magnitude of clinical benefit.
Endpoints and Statistical Analysis
Approvals were classified according to the type of primary endpoint that led to approval-OS, progression (PFS or time to progression [TTP]), or RR. The median magnitude of benefit was calculated for trials that included a comparator arm.
RESULTS
Approvals
Between January 2002 and July 2015, 63 FDA HMrelated approvals for new drugs or novel indications for previously approved drugs were identified, covering 16 different therapy areas (Table 1) . These approvals included 35 different drugs, of which 14 received multiple approvals during the period examined ( Table 2 ). The most common therapy areas were multiple myeloma (n 5 12) and chronic myeloid leukemia (n 5 10). One approval (mercaptopurine for acute lymphoblastic leukemia) was excluded because it used clinical pharmacology data rather than clinical endpoints as the basis for approval.
Endpoints Leading to FDA Approval
The primary endpoints that led to FDA approval are listed in Tables 1 and 2 and are summarized in Figure 1 . No trial had coprimary endpoints with multiple categories of survival, progression, or response. Most approvals included RR (71.4%; n 5 45). Overall, 17 approvals (27%) included progression endpoints, including PFS (n 5 14) and TTP (n 5 3). Only 1 approval (1.6%) included OS-rituximab, as a novel first-line treatment for diffuse large B-cell lymphoma, which was granted in 2006.
There was no discernible trend over time regarding the use of different endpoints for approval. RR was used relatively consistently throughout the study period. Before Abbreviations: OS, overall survival; PFS, progression-free survival; RR, response rate; T-LBL, T-cell lymphoblastic lymphoma; TTP, time to progression.
2006, only 1 approval included progression endpoints (imatinib; PFS).
Magnitude of Benefit
Overall, 23 approvals (36.5%) were of trials that included an active comparator arm. Of these approvals, 16 included median progression endpoints in the approved label. Fewer initial approvals were of studies that included a comparator arm (6 of 32 approvals) relative to expanded approvals (17 of 31 approvals). The median magnitude of benefit versus comparator was a 71% improvement (range, 26%-127%), with a median hazard ratio of 0.55 (range, 0.16-0.72).
COMMENT
In this retrospective analysis, all but 1 FDA drug approval for HMs between 2002 and 2015 included non-OS Abbreviations: ALCL, anaplastic large cell lymphoma; ALL, acute lymphocytic leukemia; CLL, chronic lymphocytic leukemia; CML, chronic myeloid leukemia; CTCL, cutaneous T-cell lymphoma; HL, Hodgkin lymphoma; MDS, myelodysplastic syndromes; MM, multiple myeloma; MCL, mantle cell lymphoma; OS, overall survival; NHL, non-Hodgkin lymphoma; PFS, progression-free survival; PTCL, peripheral T-cell lymphoma; RR, response rate; TCL, T-cell lymphoma; TTP, time to progression; WM, Waldenstrom macroglobulinemia. a The number of studies included/therapy area were: ALCL, n 5 1; ALL, n 5 7; ALL/Lymphoma, n 5 1; CLL, n 5 8; CML, n 5 10; CTCL, n 5 2; HL, n 5 2; lymphoma, n 5 2; lymphoma/NHL, n 5 1; MCL, n 5 3; MDS, n 5 4; MM, n 5 12; NHL, n 5 6; PTCL, n 5 2; TCL, n 5 1; WM, n 5 1.
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Cancer May 15, 2017 endpoints. This is consistent with studies in published literature and suggests that the FDA is willing to consider response and progression as appropriate measures for determining the benefits of new treatments for HMs. The results of this analysis are consistent with other published reports. In a review of 68 oncology drugs approved by the FDA between 1973 and 2006, Tsimberidou et al 6 observed that 31 were approved without a randomized trial, of which most included RR and other non-OS endpoints, and all but 1 drug (gefitinib) had retained approval at the time of the report in 2009. This indicated that approvals in which non-OS endpoints were included have a good record of long-term efficacy and safety. Notably, 13 of the 31 drugs were initially approved for use in leukemias, such as acute lymphocytic leukemia (asparginase, pegaspargase, and clofarabine), acute myeloid leukemia (gemtuzumab ozogamicin), chronic lymphocytic leukemia (fludarabine), and chronic myelogenous leukemia (intravenous busulfan). 6 The introduction of accelerated approval is likely to have increased the number of approvals that included non-OS endpoints; however, Johnson et al reported that, although 14 of 14 (100%) accelerated approvals granted between 1990 and 2002 included non-OS endpoints, a considerable proportion of regular approvals (39 of 57; 68.4%) also included non-OS endpoints. 2 It was noted that several of these regular approvals (pentostatin, cladribine, tretinoin, arsenic trioxide, and fludarabine) were for HMs and were based on durable RRs. Taken together, these findings confirm the role of non-OS endpoints in the development of novel treatment approaches for HMs.
Improved OS remains the gold standard for oncology trials, but this does not preclude a role for PFS, RR, and other endpoints in certain situations. In HMs, which are often characterized by prolonged OS times in part because of multiple subsequent lines of therapy, using OS as the only endpoint to demonstrate benefit of an individual treatment is fraught with challenges. These include the long study duration required to determine median OS, confounding factors associated with crossover and/or subsequent lines of therapy, and the lack of an established standard-of-care comparator. 5, 7 Focusing on OS also diminishes the importance of other key factors that demonstrably affect outcomes in patients with HMs, such as transfusion burden in myelodysplastic syndromes 8, 9 or the association of myeloma relapse with end-organ damage and higher treatment cost. 10 Although regulatory decisions support the use of PFS, RR, and other measures as clinical endpoints in HMs, these endpoints continue to be refined. For example, FDA guidance in 2012 for the evaluation of PFS in cancer was explicitly limited to non-HMs, 11 ostensibly in recognition of the differences between HMs and solid tumors. In 2013, the European Medicines Agency recommended the endpoint "PFS2" (defined as the time from randomization to second objective tumor progression, time after next-line treatment, or time to death from any cause) to evaluate the efficacy of maintenance therapy in HM trials.
12 PFS2 was introduced to help address the contribution of subsequent therapy and to determine whether the experimental treatment negatively affects the efficacy of subsequent therapy. [12] [13] [14] In patients undergoing first-line therapy for follicular lymphoma, it has been demonstrated that a complete response (CR) at 30 months is an early surrogate endpoint for PFS 15 ; whereas, in myeloma [16] [17] [18] and acute leukemias, 5 increasingly sensitive methods for detecting minimal residual disease have led to more stringent response criteria and monitoring of response.
Despite the advantages of using CR as the basis for drug approval in HMs, there are several limitations. A CR does not always correlate with increased OS, and it has been demonstrated that CRs of short duration have little impact on OS. 5 With some agents, such as azacitidine 19 and lenalidomide, 20 CR may not be required for a survival benefit. It is also possible that responses short of a CR may also be of clinical benefit. For example, in patients aged >60 years with relapsed acute myeloid leukemia treated with gemtuzumab ozogamicin, achievement of CR without full platelet recovery (CRi) was associated with an OS similar to that achieved with traditional CR. 21, 22 However, this was not the case with a recent study of clofarabine in patients with newly diagnosed acute myeloid leukemia. Foran et al 23 highlighted findings that CRi may be associated with higher levels of minimal residual disease compared with CR and that, after 12 months, the benefit of CRi was inferior to CR. 23 Finally, it should be noted that there is no single endpoint or outcome measure that can be described as a gold standard in this area and that an RR does not necessarily reflect patient quality of life, a measure that is becoming increasingly important to regulators.
The variety of endpoints used in HM trials highlights the increasing importance of defining "clinically meaningful benefit" and "treatment value." Definitions of clinically meaningful benefit vary and evolve over time, depending on current standards, expected outcomes, patient preference, and patient-reported outcomes.
1 Several organizations have developed general frameworks for assessing treatment value in oncology, but their applicability to HMs may be limited. 3, 4 The ESMO Magnitude of Clinical Benefit Scale allows for comparison of the magnitude of clinical benefit between clinical trials that use different designs and endpoints by weighting efficacy outcomes and adjusting for secondary outcomes and toxicity. 4 Separate scales were developed for curative and noncurative settings, but the scales explicitly apply only to solid tumors. Similarly, the American Society of Clinical Oncology's Value in Cancer Care Task Force developed a framework for assessing treatment value based on efficacy, safety, and cost 24 -a framework that was subsequently revised based on input from physicians, scientists, and advocacy groups. 3 The framework was applied to examples of patients who receive first-line therapy for both multiple myeloma and chronic lymphocytic leukemia; however, as part of its design, a distinction is made between adjuvant therapy and treatment for advanced disease. Also, emphasis on OS, which scores higher than PFS or RR endpoints, 3, 24 suggest that this framework may have limited applicability for HMs, and practitioners will face challenges in using these tools to score medications in HMs.
Defining clinically meaningful benefit and treatment value in HMs is vital and should be integrated into the approval process for new treatments. Effective assessment of the value of cancer therapy must be informed by a clear understanding of the distinctions between outcomes for solid tumors and HMs and realistic expectations regarding the nature and magnitude of meaningful benefit. Initiatives for HMs should account for efficacy and include accepted endpoints like PFS and RR as well as toxicity, cost, and patient preference. The use of an improvement in OS as the threshold for success in HM trials may set the bar unrealistically high and slow access to new therapies for potentially lethal diseases. 25 Leading oncologists have advocated relaxing thresholds to approve agents based on high RRs from phase 1 and 2 trials in defined subpopulations rather than mandating timeconsuming, costly phase 3 trials. 1, 25 These advocates hope that adapting such strategies may improve patient outcomes and provoke competition to reduce costs while achieving the principal aim of rapidly developing inexpensive, effective new therapies 25 ; however, definitions of acceptable RRs leading to approval have yet to be established, and they most certainly would need to be individualized for each malignancy or even for each subgrouping of the cancers under study. In summary, this retrospective review confirmed that FDA drug approvals for HMs often include non-OS endpoints like PFS and RR. The reliance of therapeutic advances in HMs on these endpoints should be taken into account when developing methods for determining the magnitude of clinical benefit and treatment value.
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